116 results about "Prediabetes" patented technology

Novel methods for assessing the state of a diabetic condition of a subject are described, comprising determining the amount of a metabolite in a sample from a body fluid or tissue of the subject. The methods may be used, for example, in diagnosing and monitoring insulin resistance, prediabetes, or the response to a drug which alters a diabetic condition.

The present invention relates to methods for modulating the intestinal microbiota by administering one or more defensins and / or GLP-1 / GLP-1 analogs and methods for prevention or treatment of gut inflammation by oral administration of one or more defensins. GLP-1 analogs such as Liraglutide, as well as mammalian and poultry alfa and beta defensins can cause a change in the composition of the microbiota and metabolome in the intestine and can therefore be used to treat or prevent gut inflammation, colorectal cancer, metabolic syndrome, obesity, prediabetes and diabetes or as lean growth promoters in the meat production.

Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation / prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation. Such drop in TG by AEC reverses maladies of insulin resistance (IR) and metabolic syndrome (MS), prediabetes, diabetes and diabetes-related cardiovascular diseases (CVD). GG activates PPAR and down regulates SREBP transcription factors. This AEC, containing GG, inhibits cancer growth whether or not GG involvement in protein prenylation is required.